Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-23
2007-10-23
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100
Reexamination Certificate
active
10284740
ABSTRACT:
The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and/or an abnormal responsivity to, interferon. Alzheimer's disease, HIV infection, Down syndrome, transplant rejection, autoimmune disease, and infant encephalitis are examples of such diseases. Specifically, the invention provides a method for treating subjects suffering from, or at risk for, such diseases by the administration of a pharmacological preparation of interferon binding proteins of mammalian and/or viral origin that antagonize interferon's action. This invention comprises compositions of interferon binding proteins that can inhibit the activity of interferon gamma plus interferon alpha such compositions along with their method of production and modification being described herein.
REFERENCES:
patent: 4766106 (1988-08-01), Katre et al.
patent: 4824432 (1989-04-01), Skurkovich et al.
patent: 4948738 (1990-08-01), Banchereau et al.
patent: 4973556 (1990-11-01), Bove et al.
patent: 5297562 (1994-03-01), Potter
patent: 5780027 (1998-07-01), Maroun
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 6093405 (2000-07-01), Zagury et al.
patent: 2006/0099224 (2006-05-01), Kim
Colamonici et al., J. of Biol. Chem., Jul. 7, 1995, 270(27):15974-78.
Smith et al., WO 92/07944, May 17, 1992.
Stewart et al., EP 0601052, Oct. 16, 1996.
Shin et al., PNAS 92:2820-2824, Mar. 1995.
Biwas et al., J. of Exp. Med., Sep. 1, 1992, 176(3):739-50.
Capobianchi et al., AIDS Res. & Human Retroviruses, 9(10):957-62, 1993.
Yamada et al. Neurosci Lett. 1994; 7: 181: 61-64.
Li et al. BMC Medical Genetics. 2006; 7: 24.
Skurkovich et al. Ann NY Acad Sci. 2005; 1051: 684-700.
Borg et al. Curr Opin Rhematol. 2007; 19: 61-66.
O'Shea, J.J. et al., (2002), “Cytokines and Autoimmunity”,Nature Reviews Immunology, 2:37-45.
Le Page, C. et al., (2000), “Interferon activation and innate immunity”,Reviews in Immunogenetics, 2:374-386.
Blasko, I. et al., (1999), “TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs”,The FASEB Journal, 13:63-68.
Gringeri, A. et al., (1999), “Active Anti-Interferon-α Immunization: A European-Israeli, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in 242 HIV-1-Infected Patients (the EURIS Study)”,Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 20(4):358-370.
Akwa, Y. et al., (1998), “Transgenic Expression of IFN-α in the Central Nervous System of Mice Protects Against Lethal Neurotropic Viral Infection but Induces Inflammation and Neurodegeneration”,The Journal of Immunology, 161:5016-5026.
Maroun, L.E. et al., (1998), “The Untoward Side Effects of Interferon Therapy Correlate Well with the Spectrum of Symptoms that Make Up the Down Syndrome”,Down Syndrome Research and Practice, 5(3):143-147.
Wiseman, B.F. et al., (1997), “Interferon and trisomy 16 mouse fetal heart development and function”,Cytogenet Cell Genet, 77(Suppl. 1):30(Abstract).
Gringeri, A. et al., (1996), “Absence of Clinical, Virological, and Immunological Signs of Progression in HIV-1-Infected Patients Receiving Active Anti-Interferon-α Immunization: A 30-Month Follow-Up Report”,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13(1):55-67.
Alcamí, A. et al., (1995), “Vaccinia, Cowpox, and Camelpox Viruses Encode Soluble Gamma Interferon Receptors with Novel Broad Species Specificity”,Journal of Virology, 69(8):4633-4639.
Fall, L.S. et al., (1995), “Biological effect of active anti-IFNα immunization in HIV-infected patients”,Biomed&Pharmacother, 49:422-428.
Gringeri, A. et al., (1995), “Anti-Alpha Interferon Immunization: Safety and Immunogenicity in Asymptomatic HIV Positive Patients at High Risk of Disease Progression”,Cellular and Molecular Biology, 41(3):381-387.
Moosmayer, D. et al., (1995), “A Bivalent Immunoadhesin of the Human Interferon-γ Receptor Is an Effective Inhibitor of IFN-γ Activity”,Journal of Interferon and Cytokine Research, 15:1111-1115.
Przemioslo, R.T. et al., (1995), “Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon γ antibody”,Gut, 36:874-879.
Symons, J.A. et al., (1995), “Vaccinia Virus Encodes a Soluble Type I Interferon Receptor of Novel Structure and Broad Species Specificity”,Cell, 81:551-560.
Lachgar, A. et al., (1994), “Involvement of α-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment”,Biomed&Pharmacother, 48:73-77.
Gringeri, A. et al., (1994), “A Randomized, Placebo-Controlled, Blind Anti-AIDS Clinical Trial: Safety and Immunogenicity of a Specific Anti-IFNα Immunization”,Journal of Acquired Immune Deficiency Syndromes, 7(9):978-988.
Soh, J. et al., (1994), “Expression of a Functional Human Type I Interferon Receptor in Hamster Cells: Application of Functional Yeast Artificial Chromosome (YAC) Screening”,The Journal of Biological Chemistry, 269(27):18102-18110.
Youngman, K.R. et al., (1994), “Inhibition of IFN-γ Activity in Supernatants from Stimulated Human Intestinal Mononuclear Cells Prevents Up-Regulation of the Polymeric Ig Receptor in an Intestinal Epithelial Cell Line”,J. Immunology, 153:675-681.
Gerdes, A.M. et al., (1993), “Effect of increased gene dosage expression of the α-interferon receptors in Down's Syndrome”,Biochimica et Biophysica Acta, 1181-135-140.
Haak-Frendscho, M. et al., (1993), “Inhibition of interferon-γ by an interferonγ receptor immunoadhesin”,Immunology, 79:594-599.
Soh, J. et al., (1993), “Identification of a yeast artificial chromosome clone encoding an accessory factor for the human interferon γ receptor: Evidence for multiple accessory factors”,Proc. Natl. Acad. Sci. USA, 90:8737-8741.
Holtzman, D.M. et al., (1992), “Dysregulation of gene expression in mouse trisomy 16, an animal model of Down Syndrome”,The EMBO Journal, 11(2):619-627.
Sen, G.C. et al., (1992), “The Interferon System”,The Journal of Biological Chemistry, 267(8):5017-5020.
Groner, Y. et al., (1990), “Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene”,J. Physiol. Paris, 84:53-77.
Jung, V. et al., (1990), “Expression and Reconstitution of a Biologically Active Human Interferon-γ Receptor in Hamster Cells”,The Journal of Biological Chemistry, 265(4):1827-1830.
Kato, K. et al., (1990), “Enhancement of S-100β Protein in Blood of Patients with Down's Syndrome”,J. Mol. Neurosci., 2:109-113.
Mann, D.M.A. et al., (1990), “The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease”,Acta Neuropathol, 80:318-327.
Bersu, E.T. et al., (1989), “Altered Placental Morphology Associated with Murine Trisomy 16 and Murine Trisomy 19”,Teratology, 40:513-523.
Cronk, C. et al., (1988), “Growth Charts for Children with Down Syndrome: 1 Month to 18 Years of Age”,Pediatrics, 81(1):102-110.
Plioplys, A.V., (1988), “Expression of the 210 kDa neurofilament subunit in culture central nervous system from normal and trisomy 16 mice: regulation by interferon”,Journal of the Neurological Sciences, 85:209-222.
Gearhart, J.D. et al., (1986), “Autosomal Aneuploidy in Mice: Generation and Developmental Consequences”,Brain Research Bulletin, 16:789-801.
Wisniewski, K.E. et al., (1986), “Neuronal Density and Synaptogenesis in the Postnatal Stage of Brain Maturation in Down Syndrome”,The Neurobiology of Down Syndrome, 29-44.
Kemmerer Elizabeth C.
McDermott Will & Emery LLP
Meiogen Biotechnology Corporation
LandOfFree
Interferon antagonists useful for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon antagonists useful for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon antagonists useful for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886132